Grants per year
Personal profile
Research Interests
Development of novel patient derived orthotopic xenograft mouse models, understand tumor biology and identify new diagnostic and/or therapeutic targets, perform comprehensive preclinical drug testing to establish preclinical rational for the initiation of clinical trials.
Nonn.
Training Experience
| 1990 | Residency, Suzhou Medical College/Soochow University, PR.China |
| 1992 | Fellowship, Suzhou Medical College/Soochow University, PR.China |
| 2001 | Postdoctoral Fellowship, Baylor College Of Medicine |
Education/Academic qualification
PhD, Suzhou Medical College/Soochow University
… → 1993
MD, Suzhou Medical College/Soochow University
… → 1985
Fingerprint
Dive into the research topics where Xiaonan Li is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants
- 2 Active
-
Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies
Qi, L., Lindsay, H., Kogiso, M., Du, Y., Braun, F. K., Zhang, H., Guo, L., Zhao, S., Injac, S. G., Baxter, P. A., Su, J. M., Xiao, S., Erickson, S. W., Earley, E. J., Teicher, B., Smith, M. A. & Li, X. N., Feb 2022, In: Laboratory Investigation. 102, 2, p. 185-193 9 p.Research output: Contribution to journal › Article › peer-review
-
Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models
Li, F., Bondra, K. M., Ghilu, S., Studebaker, A., Liu, Q., Michalek, J. E., Kogiso, M., Li, X., Kalapurakal, J. A., James, C. D., Burma, S., Kurmasheva, R. T. & Houghton, P. J., Sep 1 2022, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 28, 17, p. 3836-3849 14 p.Research output: Contribution to journal › Article › peer-review
-
Retraction Note: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma (Nature Neuroscience, (2020), 10.1038/s41593-020-0628-4)
Garancher, A., Suzuki, H., Haricharan, S., Chau, L. Q., Masihi, M. B., Rusert, J. M., Norris, P. S., Carrette, F., Romero, M. M., Morrissy, S. A., Skowron, P., Cavalli, F. M. G., Farooq, H., Ramaswamy, V., Jones, S. J. M., Moore, R. A., Mungall, A. J., Ma, Y., Thiessen, N., Li, Y., & 20 others, Jan 2022, In: Nature neuroscience. 25, 1, p. 127 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma
Kogiso, M., Qi, L., Du, Y., Braun, F. K., Zhang, H., Huang, L. F., Guo, L., Huang, Y., Teo, W. Y., Lindsay, H., Zhao, S., Injac, S. G., Liu, Z., Mehta, V., Tran, D., Li, F., Baxter, P. A., Su, J. M., Perlaky, L., Parsons, D. W., & 4 others, Apr 2022, In: Translational Oncology. 18, 101368.Research output: Contribution to journal › Article › peer-review
Open Access -
Corrigendum to “Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors” [Cancer Lett. 493 (2020) 197–206] (Cancer Letters (2020) 493 (197–206), (S0304383520304493), (10.1016/j.canlet.2020.08.035))
Qi, L., Kogiso, M., Du, Y., Zhang, H., Braun, F. K., Huang, Y., Teo, W. Y., Lindsay, H., Zhao, S., Baxter, P., Zhao, X., Yu, L., Liu, Z., Zhang, X., Su, J., Adesina, A., Yang, J., Chintagumpala, M., Perlaky, L., Tsz-Kwong Man, C., & 2 others, Mar 1 2021, In: Cancer Letters. 500, p. 294 1 p.Research output: Contribution to journal › Comment/debate › peer-review